- Home
- ALNY vs TFC Comparison
ALNY vs TFC Comparison
Compare ALNY & TFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | TFC |
|---|---|---|
| Founded | 2002 | 1872 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.9B | 63.5B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALNY | TFC |
|---|---|---|
| Price | $358.77 | $49.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 14 |
| Target Price | ★ $482.77 | $53.85 |
| AVG Volume (30 Days) | 1.3M | ★ 8.6M |
| Earning Date | 02-12-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 4.20% |
| EPS Growth | N/A | ★ 13.86 |
| EPS | 0.33 | ★ 3.82 |
| Revenue | $3,210,070,000.00 | ★ $18,425,000,000.00 |
| Revenue This Year | $70.40 | $17.70 |
| Revenue Next Year | $43.15 | $4.17 |
| P/E Ratio | $1,085.60 | ★ $12.98 |
| Revenue Growth | 53.24 | ★ 61.51 |
| 52 Week Low | $205.87 | $33.56 |
| 52 Week High | $495.55 | $51.52 |
Technical Indicators
Market Signals| Indicator | ALNY | TFC |
|---|---|---|
| Relative Strength Index (RSI) | 34.07 | 48.78 |
| Support Level | $348.13 | $47.83 |
| Resistance Level | $376.87 | $51.14 |
| Average True Range (ATR) | 16.74 | 1.12 |
| MACD | -1.16 | -0.21 |
| Stochastic Oscillator | 13.65 | 44.10 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About TFC Truist Financial Corporation
Truist Financial is one of the three super-regional banks in the US, with roughly $545 billion in assets as of the second quarter of 2025. Truist emerged from the combination of BB&T and SunTrust in 2019. Based in Charlotte, North Carolina, the bank's footprint is largely in the Mid-Atlantic and Southeast. Apart from retail and commercial banking operations, the bank also offers online and point-of-sale consumer lending, cards, wealth management, investment banking, and other banking services.